{"title":"Advances in transmission-blocking vaccines against <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i>.","authors":"Mayumi Tachibana, Eizo Takashima, Motomi Torii, Yimin Wu, Jetsumon Sattabongkot, Takafumi Tsuboi","doi":"10.1080/14760584.2025.2517720","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The World Health Organization has recommended two pre-erythrocytic malaria vaccines targeting Plasmodium falciparum. However, there is currently no vaccine available for Plasmodium vivax, the second leading cause of malaria. To eliminate malaria, transmission-blocking vaccines (TBVs) that can prevent infection of mosquitoes from humans would be helpful.</p><p><strong>Areas covered: </strong>This review summarizes the identification of targets, progress, and prospects in developing malaria TBVs. We searched PubMed for studies published up to 11 April 2025, using the terms ['Pfs25' OR 'Pfs230' OR 'Pfs48/45' OR 'Pvs25' OR 'Pvs230' OR 'Pvs48/45' OR 'AnAPN1'] AND ['malaria transmission-blocking vaccine'].</p><p><strong>Expert opinion: </strong>After over 30 years of research and development, Pfs230 for P. falciparum and Pvs25 for P. vivax are the most advanced candidates for transmission-blocking vaccines.</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"509-523"},"PeriodicalIF":5.5000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2025.2517720","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/18 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: The World Health Organization has recommended two pre-erythrocytic malaria vaccines targeting Plasmodium falciparum. However, there is currently no vaccine available for Plasmodium vivax, the second leading cause of malaria. To eliminate malaria, transmission-blocking vaccines (TBVs) that can prevent infection of mosquitoes from humans would be helpful.
Areas covered: This review summarizes the identification of targets, progress, and prospects in developing malaria TBVs. We searched PubMed for studies published up to 11 April 2025, using the terms ['Pfs25' OR 'Pfs230' OR 'Pfs48/45' OR 'Pvs25' OR 'Pvs230' OR 'Pvs48/45' OR 'AnAPN1'] AND ['malaria transmission-blocking vaccine'].
Expert opinion: After over 30 years of research and development, Pfs230 for P. falciparum and Pvs25 for P. vivax are the most advanced candidates for transmission-blocking vaccines.
期刊介绍：
Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review.
The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
